Phospho-PBK (Thr9) Recombinant Antibody

$Western blot analysis of (1) HeLa cell lysate; (2) HeLa cell treated with Nocodazole lysate. Using Phospho-PBK (Thr9) (bsm-62741R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n$

Western blot analysis of (1) HeLa cell lysate; (2) HeLa cell treated with Nocodazole lysate. Using Phospho-PBK (Thr9) (bsm-62741R) monoclonal antibody at 1:1000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.\r\n

Applications

WB
IHC-P
IHC-F
IF

Reactivity

Human

Overview
Catalog #	bsm-62741r
Product Name	Phospho-PBK (Thr9) Recombinant Antibody
Applications	WB, IHC-P, IHC-F, IF
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human PBK around the phosphorylation site of T9
Modification Site	Thr9
Clonality	Recombinant
Isotype	IgG
Concentration	Lot dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	55872
Swiss Prot	Q96KB5
Synonyms	CT84; MAPKK like protein kinase; Nori3; PBK; PDZ binding kinas; Serine/threonine protein kinase; SPK; TOPK.
Background	Phosphorylates MAP kinase p38. Seems to be active only in mitosis. May also play a role in the activation of lymphoid cells. When phosphorylated, forms a complex with TP53, leading to TP53 destabilization and attenuation of G2/M checkpoint during doxorubicin-induced DNA damage.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400
IHC-F	1:100-500
IF